Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05558267 · ClinicalTrials.gov registry record · NA
Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease
A NA study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT05558267 is a NA study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 20 participants.
The verdict
NCT05558267, a NA study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration will be measured bi-weekly prior to HD each week during intervention. The primary endpoint will be the change in potassium from baseline. Additional measurements will include assessment of dietary intake, ambulatory blood pressure, occurrence of peri-dialytic symptoms, and per-dialytic vital signs.
Interventions
- DIETARY_SUPPLEMENT Standard Table Salt
- DIETARY_SUPPLEMENT Salt Substitute
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2027-01-15 |
| Est. Completion | 2027-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05558267
The ClinicalTrials.gov registry entry for NCT05558267 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Table Salt is the first listed.
NCT05558267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05558267 about?
NCT05558267 is a clinical study titled "Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease". 16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration wi...
What is the current status of trial NCT05558267?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2027-01-15. Estimated completion is 2027-06-15.
What interventions are being tested in trial NCT05558267?
The interventions under investigation include: Standard Table Salt (DIETARY_SUPPLEMENT), Salt Substitute (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05558267?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.